Several features of COPD (dyspnea, air hunger, functional decline, and the possibility of mechanical ventilation) commonly force patients and physicians to confront end-of-life issues. Chronic ...

Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD).

Two posters at the CHEST 2024 annual meeting revealed that 18% of eligible patients hospitalized with acute exacerbations of ...

For the 16 million Americans with chronic obstructive pulmonary disease (COPD), travel can be as anxiety-provoking as it is life-affirming. The fatigue, chest tightness, congestion, and difficulty ...

Carpets, fireworks, and hot tubs are some of the unexpected things that can hurt your lungs. Find out what you can do to prevent problems from these and other culprits.

She volunteered as a patient advocate and formed a nonprofit, the Hawaii COPD Coalition, which holds support groups. “It’s terribly isolating to be diagnosed with COPD, especially when you are ...

And it doesn't give future doctors ... Apr. 23, 2024 — Patients have lower rates of mortality and hospital readmissions when treated by female physicians, with female patients benefitting more ...

Patients with COPD and type 2 diabetes using SGLT2i were much less likely to have ER visits and hospitalizations related to COPD exacerbations.

physical examination communication history taking patient counseling patient education Professional trainers, staff, and faculty members prepare standardized patients for their roles in all assigned ...

The FDA approved dupilumab (Dupixent; Regeneron/Sanofi) today for treating patients with uncontrolled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. 1 This approval ...

With the label expansion, Dupixent becomes the first biologic treatment for COPD patients in the U.S. The IL-4 and IL-13 inhibitor is approved to be used as an add-on maintenance treatment by ...

The company has said it expects the target COPD patient population eligible for the drug to be roughly 300,000 patients in the U.S. It has anticipated steeper growth in Dupixent sales in 2025 ...